vs
奎斯特诊断（IMDX）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
Alpha Teknova, Inc.的季度营收约是奎斯特诊断的8.8倍（$10.0M vs $1.1M）。Alpha Teknova, Inc.净利率更高（-47.7% vs -2015.4%，领先1967.7%）。Alpha Teknova, Inc.同比增速更快（7.8% vs -23.4%）。Alpha Teknova, Inc.自由现金流更多（$-810.0K vs $-7.0M）。过去两年奎斯特诊断的营收复合增速更高（154.4% vs 3.7%）
奎斯特诊断公司是一家美国临床检验企业，跻身财富500强，业务覆盖美国本土，以及波多黎各、墨西哥、巴西等地区，同时与全球多家医院和诊所保持合作关系，是行业内颇具影响力的医疗诊断服务提供商。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
IMDX vs TKNO — 直观对比
营收规模更大
TKNO
是对方的8.8倍
$1.1M
营收增速更快
TKNO
高出31.1%
-23.4%
净利率更高
TKNO
高出1967.7%
-2015.4%
自由现金流更多
TKNO
多$6.2M
$-7.0M
两年增速更快
IMDX
近两年复合增速
3.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $10.0M |
| 净利润 | $-23.0M | $-4.8M |
| 毛利率 | 42.5% | 32.5% |
| 营业利润率 | -2057.5% | -46.2% |
| 净利率 | -2015.4% | -47.7% |
| 营收同比 | -23.4% | 7.8% |
| 净利润同比 | 31.5% | 16.8% |
| 每股收益（稀释后） | $-0.75 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMDXTKNO
| Q4 25 | $1.1M | $10.0M | ||
| Q3 25 | $260.0K | $10.5M | ||
| Q2 25 | $518.0K | $10.3M | ||
| Q1 25 | $2.1M | $9.8M | ||
| Q4 24 | $1.5M | $9.3M | ||
| Q3 24 | $115.0K | $9.6M | ||
| Q2 24 | $104.0K | $9.6M | ||
| Q1 24 | $176.0K | $9.3M |
净利润IMDXTKNO
| Q4 25 | $-23.0M | $-4.8M | ||
| Q3 25 | $-10.9M | $-4.3M | ||
| Q2 25 | $-9.7M | $-3.6M | ||
| Q1 25 | $-6.7M | $-4.6M | ||
| Q4 24 | $-33.5M | $-5.7M | ||
| Q3 24 | $-13.5M | $-7.6M | ||
| Q2 24 | $-4.5M | $-5.4M | ||
| Q1 24 | $-9.1M | $-8.1M |
毛利率IMDXTKNO
| Q4 25 | 42.5% | 32.5% | ||
| Q3 25 | 53.5% | 30.7% | ||
| Q2 25 | 67.6% | 38.7% | ||
| Q1 25 | 62.0% | 30.7% | ||
| Q4 24 | 40.0% | 23.0% | ||
| Q3 24 | 43.5% | 0.9% | ||
| Q2 24 | 48.1% | 29.2% | ||
| Q1 24 | 25.6% | 23.8% |
营业利润率IMDXTKNO
| Q4 25 | -2057.5% | -46.2% | ||
| Q3 25 | -4249.2% | -38.4% | ||
| Q2 25 | -1900.0% | -32.9% | ||
| Q1 25 | -318.0% | -50.7% | ||
| Q4 24 | -2262.9% | -60.7% | ||
| Q3 24 | -11752.2% | -77.6% | ||
| Q2 24 | -4453.8% | -53.0% | ||
| Q1 24 | -5265.3% | -86.0% |
净利率IMDXTKNO
| Q4 25 | -2015.4% | -47.7% | ||
| Q3 25 | -4174.6% | -41.0% | ||
| Q2 25 | -1880.7% | -34.7% | ||
| Q1 25 | -312.0% | -47.4% | ||
| Q4 24 | -2255.1% | -61.7% | ||
| Q3 24 | -11733.0% | -79.0% | ||
| Q2 24 | -4355.8% | -55.8% | ||
| Q1 24 | -5186.9% | -87.2% |
每股收益（稀释后）IMDXTKNO
| Q4 25 | $-0.75 | $-0.08 | ||
| Q3 25 | $-0.34 | $-0.08 | ||
| Q2 25 | $-0.30 | $-0.07 | ||
| Q1 25 | $-0.26 | $-0.09 | ||
| Q4 24 | $-2.19 | $-0.09 | ||
| Q3 24 | $-0.98 | $-0.15 | ||
| Q2 24 | $-0.36 | $-0.13 | ||
| Q1 24 | $-1.13 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.6M | $21.3M |
| 总债务越低越好 | — | $13.1M |
| 股东权益账面价值 | $-31.5M | $68.8M |
| 总资产 | $25.8M | $103.6M |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资IMDXTKNO
| Q4 25 | $11.6M | $21.3M | ||
| Q3 25 | $18.7M | $22.1M | ||
| Q2 25 | $24.3M | $24.0M | ||
| Q1 25 | $31.0M | $26.3M | ||
| Q4 24 | $8.6M | $30.4M | ||
| Q3 24 | $3.4M | $31.7M | ||
| Q2 24 | $9.3M | $18.6M | ||
| Q1 24 | $5.6M | $21.6M |
总债务IMDXTKNO
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $12.3M | ||
| Q1 24 | — | $13.2M |
股东权益IMDXTKNO
| Q4 25 | $-31.5M | $68.8M | ||
| Q3 25 | $-9.2M | $72.7M | ||
| Q2 25 | $1.1M | $76.1M | ||
| Q1 25 | $10.2M | $78.6M | ||
| Q4 24 | $-12.3M | $82.4M | ||
| Q3 24 | $9.7M | $87.3M | ||
| Q2 24 | $22.7M | $78.9M | ||
| Q1 24 | $11.6M | $83.4M |
总资产IMDXTKNO
| Q4 25 | $25.8M | $103.6M | ||
| Q3 25 | $43.9M | $107.6M | ||
| Q2 25 | $50.5M | $110.5M | ||
| Q1 25 | $60.4M | $114.0M | ||
| Q4 24 | $35.1M | $118.8M | ||
| Q3 24 | $70.2M | $124.1M | ||
| Q2 24 | $74.7M | $115.4M | ||
| Q1 24 | $71.0M | $120.8M |
负债/权益比IMDXTKNO
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | $-7.0M | $-810.0K |
| 自由现金流率自由现金流/营收 | -616.7% | -8.1% |
| 资本支出强度资本支出/营收 | 129.9% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-25.4M | $-9.8M |
8季度趋势，按日历期对齐
经营现金流IMDXTKNO
| Q4 25 | $-5.5M | $-462.0K | ||
| Q3 25 | $-4.5M | $-2.0M | ||
| Q2 25 | $-6.3M | $-2.1M | ||
| Q1 25 | $-5.9M | $-4.1M | ||
| Q4 24 | $-5.4M | $-936.0K | ||
| Q3 24 | $-5.5M | $-2.1M | ||
| Q2 24 | $-6.0M | $-2.8M | ||
| Q1 24 | $-3.8M | $-6.6M |
自由现金流IMDXTKNO
| Q4 25 | $-7.0M | $-810.0K | ||
| Q3 25 | $-5.6M | $-2.4M | ||
| Q2 25 | $-6.6M | $-2.3M | ||
| Q1 25 | $-6.2M | $-4.3M | ||
| Q4 24 | $-5.6M | $-1.5M | ||
| Q3 24 | $-5.6M | $-2.4M | ||
| Q2 24 | $-6.2M | $-3.0M | ||
| Q1 24 | $-3.9M | $-6.7M |
自由现金流率IMDXTKNO
| Q4 25 | -616.7% | -8.1% | ||
| Q3 25 | -2135.4% | -22.6% | ||
| Q2 25 | -1279.5% | -22.4% | ||
| Q1 25 | -288.4% | -44.0% | ||
| Q4 24 | -374.5% | -16.2% | ||
| Q3 24 | -4884.3% | -25.0% | ||
| Q2 24 | -5931.7% | -30.7% | ||
| Q1 24 | -2189.8% | -71.8% |
资本支出强度IMDXTKNO
| Q4 25 | 129.9% | 3.5% | ||
| Q3 25 | 403.8% | 3.7% | ||
| Q2 25 | 67.4% | 2.0% | ||
| Q1 25 | 14.4% | 2.1% | ||
| Q4 24 | 14.4% | 6.1% | ||
| Q3 24 | 75.7% | 3.5% | ||
| Q2 24 | 183.7% | 1.2% | ||
| Q1 24 | 13.6% | 1.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMDX
暂无分部数据
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
